Aurobindo Pharma is currently trading at Rs. 107.20, up by 1.05 points or 0.99% from its previous closing of Rs. 106.15 on the BSE.
The scrip opened at Rs. 103.00 and has touched a high and low of Rs. 108.15 and Rs. 102.95 respectively. So far 61932 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 194.40 on 20-May-2011 and a 52 week low of Rs. 80.35 on 18-Nov-2011.
Last one week high and low of the scrip stood at Rs. 112.75 and Rs. 100.75 respectively. The current market cap of the company is Rs. 3115.00 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 29.39% and 15.85% respectively.
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Clopidogrel Tablets USP 75mg, which is being launched.
Clopidogrel Tablets USP 75mg is the generic equivalent of Aventis US LLC (Sanfoi’s) Plavix tablets USP 75mg. The product falls under the cardio-vascular (CVS) therapeutic category and is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease. The annual sale of the product is about $6.4 billion.
The company now has a total of 151 ANDA approvals (123 Final approvals including 1 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |